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Abstract
Background:  In order to improve the monitoring of the antimalarial drug resistance in
Madagascar, a new national network based on eight sentinel sites was set up. In 2006/2007, a multi-
site randomized clinical trial was designed to assess the therapeutic efficacy of chloroquine (CQ),
sulphadoxine-pyrimethamine (SP), amodiaquine (AQ) and artesunate plus amodiaquine
combination (ASAQ), the antimalarial therapies recommended by the National Malaria Control
Programme (NMCP).
Methods: Children between six months and 15 years of age, with uncomplicated falciparum
malaria, were enrolled. Primary endpoints were the day-14 and day-28 risks of parasitological
failure, either unadjusted or adjusted by genotyping. Risks of clinical and parasitological treatment
failure after adjustment by genotyping were estimated using Kaplan-Meier survival analysis.
Secondary outcomes included fever clearance, parasite clearance, change in haemoglobin levels
between Day 0 and the last day of follow-up, and the incidence of adverse events.
Results: A total of 1,347 of 1,434 patients (93.9%) completed treatment and follow-up to day 28.
All treatment regimens, except for the chloroquine (CQ) treatment group, resulted in clinical cure
rates above 97.6% by day-14 and 96.7% by day-28 (adjusted by genotyping). Parasite and fever
clearance was more rapid with artesunate plus amodiaquine, but the extent of haematological
recovery on day-28 did not differ significantly between the four groups. No severe side-effects
were observed during the follow-up period.
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Conclusion: These findings (i) constitute an up-dated baseline data on the efficacy of antimalarial
drugs recommended by the NMCP, (ii) show that antimalarial drug resistance remains low in
Madagascar, except for CQ, compared to the bordering countries in the Indian Ocean region such
as the Comoros Archipelago and (iii) support the current policy of ASAQ as the first-line treatment
in uncomplicated falciparum malaria.
Background
Despite major efforts made by national and international
health organizations, malaria remains the most wide-
spread infectious parasitic diseases and one of the most
serious global health problems in the world [1]. In sub-
Saharan African, the main problem is Plasmodium falci-
parum drug-resistance, especially with the spread of the
parasite resistance to the inexpensive and widely used
drugs, such as chloroquine (CQ) or sulphadoxine-
pyrimethamine (SP) [2,3], and the major consequence is
the use of ineffective antimalarial drugs leading to the
increasing malarial incidence and mortality [4,5].
Therefore, substantial efforts have been made to encour-
age the monitoring and the evaluation of the antimalarial
drugs resistance in the endemic countries for assessing
regularly their antimalarial drug policies and ensuring a
continued coverage of effective antimalarial treatment [6].
In Madagascar, since 2005, antimalarial treatment is in
transition with the elaboration and the implementation
of the new national policy for the fight against malaria [7].
The main modifications in term of drugs use has been the
withdrawal of CQ in favour of artemisinin combination
therapies (ACTs), as first-line (artesunate plus amodi-
aquine combination, ASAQ) and second-line treatment
(artemether plus lumefantrine combination), and the use
of the SP for intermittent preventive treatment for preg-
nant women (IPTp). This choice was guided by the recom-
mendations of WHO and unpublished data from a
clinical trial conducted on the island of Sainte Marie in
2004, which show 36.9% of treatment failure over the 14-
day follow-up period, unadjusted by genotyping. How-
ever, with regards to the home treatment of presumed
malaria in children (HMM), it has been decided to con-
tinue to use pre-packaged chloroquine, either PaluStop®
sold by the NGO "Population Service International" (PSI)
or Ody Tazomoka® freely distributed at primary public
health facilities by Malagasy Ministry of Health (Mal-
MoH), as transitory measure until ACTs were available at
community level [8]. At present, the implementation of
the ACTs as first-line treatment at health centres level is
complete on the east coast of Madagascar, with the result
that only 24% (31/131) of the health districts in Madagas-
car are using ACT.
Since 1999, the antimalarial drug resistance surveillance
system in Madagascar is supported by a national network
for the surveillance of malaria resistance (named RER –
Réseau d'Etude de la Résistance). The RER was formed as
a collaborative effort between the MalMoH and the
Malaria Research Unit of the Institut Pasteur de Madagas-
car (IPM). The strategy of monitoring was initially based
on the use of the in vitro assessment of P. falciparum sensi-
tivity to antimalarial drugs and the evaluation of the fre-
quency of genetic markers associated with P. falciparum
drug resistance [9,10]. In vivo studies were also carried out,
but these studies were limited geographically, the sample
sizes were small and used only a 14-day follow-up period,
a series of constraints which may have significantly under-
estimated the true risk of treatment failure [11-14].
In order to improve the monitoring of antimalarial drug
resistance in Madagascar, a new RER was set up in 2006,
with the support of Global Fund. According to the WHO
recommendation [15], this network was based on sentinel
sites located within public or private health facilities and
selected to be representative of the range of ecological and
epidemiologic conditions. The main purpose of this paper
is to report the establishment of the new RER, and to
present the up-dated baseline data from multi-site rand-
omized clinical trial assessing the therapeutic efficacy of
antimalarial therapies recommended by the National
Malaria Control Programme.
Methods
Organizational structure and study sites
The antimalarial drug efficacy trials were conducted in
two steps in eight sentinel sites located in the four differ-
ent malarious epidemiological strata throughout Mada-
gascar: from February to June 2006, in Ejeda and Ihosy in
the South Madagascar (sub-desert stratum, epidemic
prone), in Maevatanana and Miandrivazo in the West
Madagascar (tropical stratum, seasonal and endemic area)
and in Tsiroanomandidy and Moramanga in the foothills
of the Central Highlands of Madagascar (highlands stra-
tum, low-endemic area); from March to August 2007 in
Andapa and Farafangana in the East Madagascar (equato-
rial stratum, perennial endemic area) (Figure 1).
Patient enrolment
This was an open-label trial in which patients with micro-
scopically-confirmed falciparum malaria were rand-Malaria Journal 2008, 7:55 http://www.malariajournal.com/content/7/1/55
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Map of Madagascar based on malarious epidemiological strata and the eight selected sentinel sites involved for monitoring the  antimalarial drug resistance [19] Figure 1
Map of Madagascar based on malarious epidemiological strata and the eight selected sentinel sites involved for 
monitoring the antimalarial drug resistance [19].
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omized into three or four treatment groups according to
sentinel sites: CQ, amodiaquine (AQ), SP or ASAQ in
Ejeda, Ihosy, Miandrivazo, Maevatanana and Moram-
anga; CQ, AQ and SP in Tsiroanomandidy and AQ, SP
and ASAQ in Andapa and Farafangana.
All patients aged between six months and 15 years were
eligible to be enrolled and were screened for malaria at the
primary health centres in the sentinel sites on the basis of
history of febrile illness. According to the slightly modi-
fied WHO 2003 protocol [15], inclusion criteria were (i)
monoinfection with P. falciparum at a parasitaemia
between 1,000 and 200,000/μl, (ii) axillary temperature ≥
37.5°C, (iii) body weight > 5 kg, (iv) absence of severe
malnutrition, (v) absence of febrile conditions caused by
diseases other than malaria, (vi) absence of 'danger signs'
(inability to stand, breastfeeding or drink; recent convul-
sions; lethargy or persistent vomiting) and of severe and
complicated malaria, (vii) haemoglobin (Hb) ≥ 5 g/dl,
and (viii) informed written consent of parents/guardians.
Known hypersensitivity to SP, AQ, or AS was considered
as an exclusion criterion. Once written informed consent
was given, patients were enrolled in the study and
assigned consecutive patient numbers. Randomization to
treatment group was performed in blocks of three or four,
and treatment regimens were allocated by an independent
individual, not involved in the analysis of the study.
Treatment and follow-up procedures
Patients were administered either CQ (10 mg/kg on days
0 and 1, and 5 mg/kg on day 2), AQ (10 mg/kg on days 0,
1, and 2), SP (25 mg/kg sulphadoxine and 1.25 mg/kg
pyrimethamine as a single dose on day 0) or ASAQ (AS: 4
mg/kg on days 0, 1, and 2 and AQ:10 mg/kg on days 0, 1,
and 2). Patients were directly observed for 30 minutes
after treatment, and the dose was readministered if vomit-
ing occurred. Patients who repeatedly vomited their first
dose of study medication were excluded from the study.
Patients were assessed on days 1, 2, 3, 7, 14, 21 and 28,
and any intervening day they were unwell for malaria
infection. Blood was obtained by finger prick on all fol-
low-up days and on any unscheduled day to use for anal-
ysis of thick and thin blood smears and for storage on
filter paper. Thick and thin blood slides were examined by
light microscopy for parasites on any day during the 28-
day follow-up. Blood slides were read by a microscopist
blind to treatment allocation. All slides were controlled by
a second microscopist also blind to treatment group and
previous diagnosis. Discordant slides were read, blind to
treatment group and previous diagnosis, by a third micro-
scopist. Haemoglobin was measured on Day 0 and Day 28
using a HemoCue haemoglobinometre (HemoCue AB,
Ängelholm, Sweden).
Outcome measures
Treatment outcomes were assessed according to WHO
2003 guidelines as Early Treatment Failure (ETF; danger
signs or complicated malaria or failure to adequately
respond to therapy on days 0–3), Late Clinical Failure
(LCF; danger signs or complicated malaria or fever and
parasitemia on days 4–28 without previously meeting cri-
teria for ETF), Late Parasitological Failure (LPF; asympto-
matic parasitaemia on days 4–28 without previously
meeting criteria for ETF or LCF), and Adequate Clinical
and Parasitological Response (ACPR; absence of parasi-
taemia on day 28 without previously meeting criteria for
ETF, LCF, or LPF) [15]. Overall Treatment failure (OFT)
was considered as the sum of the ETP, LCT and LPF.
Patients classified as having suffered treatment failure
were treated with quinine (10 mg/kg three times daily for
seven days); however, their response to repeat therapy was
not assessed. Patients were excluded after enrolment if any
of the following occurred: (i) use of antimalarial drugs
outside of the study protocol; (ii) detection during follow-
up of mixed malarial infections (iii) parasitaemia in the
presence of a concomitant febrile illness which would
interfere with the classification of treatment outcome; (iv)
withdrawal of consent; (v) loss to follow-up, (vi) protocol
violation, or (vii) death due to a non-malaria illness.
Laboratory procedures
Blood smears were stained with 10 % Giemsa for 10 min.
Parasite densities were determined from thick blood
smears by counting the number of asexual parasites per
200 WBCs (or per 500, if the count was less than 10 para-
sites/200 WBCs), assuming a WBC count of 8,000/μl. A
smear was considered negative if no parasites were seen
after review of 100 fields. Thin blood smears were used to
detect non-falciparum infections [16].
Molecular genotyping techniques were used to distin-
guish recrudescence from new infection for all patients
failing therapy after day 7. Filter paper blood samples col-
lected on the day of enrolment, on day 1 and on the day
of failure were analysed for polymorphisms in the genes
for merozoite surface protein-1 (msp-1) and merozoite
surface protein-2 (msp-2) using nested-PCR as previously
described [17]. First, msp-2 genotyping patterns on the day
of failure were compared with those at treatment initia-
tion and on day 1, using Quantity One© software (BioRad
laboratories, Inc., 1000 Alfred Nobel Drive, Hercules, CA
94547, United States). If all of the msp-2 alleles present on
the day of failure were present at the time of treatment ini-
tiation or on day 1, genotyping was repeated using msp-1.
An outcome was defined as recrudescence if all msp-1 and
msp-2 alleles present at the time of failure were present at
the time of treatment initiation or on day 1, and defined
as a new infection otherwise.Malaria Journal 2008, 7:55 http://www.malariajournal.com/content/7/1/55
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Statistical analysis
Data were entered and verified using EpiInfo 6.04© soft-
ware (Centers for Disease Control and Prevention,
Atlanta, Georgia, United States), and analysed using Med-
Calc© software version 9.1.0.1 (MedCalc Software, Broek-
straat 52, 9030 Mariakerke, Belgium). As the proportion
of treatment failures was unknown in the sentinel sites, a
minimum of 50 patients was included for each treatment
group and each site, according to available human and
financial resources and the WHO recommendations [15].
Efficacy data were assessed with a per-protocol analysis
that included all patients who completed the study. An
age-stratified analysis for patients less than five years of
age and patients five years or older was planned. This
study was not designed for the primary analysis to be strat-
ified by site. Parasite densities were normalized using log-
arithmic transformation. Categorical variables were
compared using χ2 or Fisher's exact test, and continuous
variables were compared using an independent samples t
test.
The primary efficacy outcomes were 14-day and 28-day
clinical and parasitological failure risks both unadjusted
and adjusted by genotyping. Risks of clinical and parasito-
logical treatment failure after adjustment by genotyping
were estimated using Kaplan-Meier survival analysis tech-
niques in accordance with the new WHO protocol [15].
With survival analysis, data were censored for new infec-
tions. Secondary outcomes included fever clearance, para-
site clearance, change in haemoglobin levels between Day
0 and the last day of follow-up, and the incidence of
adverse events. Hypothesis testing was made using risk
differences, exact 95% confidence intervals, and P values.
A P value (two-tailed) of less than 0.05 was considered
statistically significant.
Ethical approval
The study protocol was reviewed and approved by the Eth-
ics Committee of the Ministry of Health of Madagascar
(N°007/SANPF/2007). An informed written consent was
provided by the parents/guardians of all patients before
they were included in the study.
Results
Enrolment
In the eight sentinel sites, 8,363 patients were screened,
with 1,873 patients positive for P. falciparum (22.4%). Of
these patients, a total of 1,434 patients were enrolled in
February-June 2006 and March-July 2007 (76.6%). A total
of 320 patients were randomized to CQ, 385 to AQ, 383
to SP, and 346 to ASAQ. The main reasons for patients
with P. falciparum not being included were non-consent,
inability to attend follow-up or concurrent disease. The
flow of patients through the trial is shown in Figure 2.
A total of 1,347 of 1,434 patients (93.9%) completed
treatment and follow-up to day 28 (92.5% in the AQ
group, 93.7% in the CQ group, 94.2% in the SP group,
and 95.4% in the ASAQ group). Eighty eight patients were
either lost to follow-up (n = 68) or excluded/withdrawn
from the trial (n = 20). Of these patients, 18 withdrew
consent, two were withdrawn due to adverse events. The
baseline characteristics of patients across the treatment
groups were similar at each site (Table 1).
Primary outcome: treatment efficacy
The results of the treatment efficacy are presented by treat-
ment group and day of follow-up in Table 2 and by age
group and study site in Tables 3 and 4. Figure 3 showed
the Kaplan-Meier curve of cumulative treatment failure
over the 28-day follow-up period, adjusted by genotyping.
All treatment regimens, except for the CQ treatment
group, resulted in clinical cure rates above 97.6% by day-
14 and 96.7% by day-28 (adjusted by genotyping). Con-
sidering all sites, the OTF of the CQ group was signifi-
cantly higher than in the other treatment group as well as
day 14 or day 28 unadjusted or adjusted by genotyping (P
< 0.0001).
In the CQ group, ETF was uncommon with only 10.6% of
the OTF (i.e., 14/132). Most of the treatment failures
adjusted by genotyping were occurred in the second/third
week of follow-up mainly as LPF (63.6%). Among the
eight sites, the OTF adjusted by genotyping of CQ was sig-
nificantly different ranging from 19% in Ihosy to 64% in
Ejeda (P < 0.0001). The risk of treatment failure adjusted
by genotyping in children less than five years old was
almost twice as frequent than in older patients (52.7% vs.
37.3%, adjusted odds ratio [OR], 1.8; 95% confidence
interval [CI], 1.2–3.0; P = 0.004). The risk of treatment
failure by day-14 was significantly lower than by day-28
adjusted by genotyping (32.0% vs. 44.0%, risk difference
12.0%, 95% CI: 4.3%–19.5%, P = 0.003).
In the SP group, treatment failures were rare with an OTF
adjusted by genotyping of 3.3%, but ETF was accounting
for more than one third of the treatment failures: Two
patients from Ejeda developed danger signs despite
decreasing parasite density, one patient from Tsiroano-
mandidy presented at day 3, a parasite density > 25% of
count on day 0 and the last patient from Maevatanana, a
parasite density with an axillary temperature ≥ 37.5°C.
The distribution of the treatment failure adjusted by gen-
otyping was not significantly different among the sites (P
= 0.08), especially because of the small number of the
patients included per site and the small number of treat-
ment failure.Malaria Journal 2008, 7:55 http://www.malariajournal.com/content/7/1/55
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Flow of patients Figure 2
Flow of patients.
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In the AQ and ASAQ groups, treatment efficacies were glo-
bally very high throughout Madagascar. Treatment fail-
ures adjusted by genotyping were not significantly
different among the sentinel sites (P = 0.24 for AQ and P
= 0.12 for ASAQ).
Table 1: Baseline characteristics by treatment group*
Treatment Group
Characteristics Chloroquine Amodiaquine Sulphadoxine-Pyrimethamine Artesunate-Amodiaquine
No. of patients enrolled 320 385 383 346
Ejeda 51 51 50 50
Ihosy 62 62 61 63
Miandrivazo 67 69 69 68
Maevatanana 55 56 56 55
Tsiroanomandidy 43 48 48 0
Moramanga 42 39 40 40
Andapa 0 32 29 41
Farafangana 0 28 30 29
Age
median (range), y 5 (0.5 – 15) 5 (0.5 – 15) 5 (0.5 – 15) 5 (0.5 – 15)
Proportion of children ≤ 5 years 142 (45.4) 185 (48.7) 182 (47.8) 167 (48.7)
Weight, median (IQR), kg 15 (6 – 58) 15 (5 – 62) 14 (6 – 60) 13 (2.6 – 56)
Female 158 (49.5) 188 (48.8) 186 (48.6) 169 (49.0)
Temperature, mean (95% CI) 38.4 (38.3 – 38.5) 38.4 (38.3 – 38.5) 38.4 (38.3 – 38.5) 38.6 (38.5 – 38.7)
Trophozoite density, geometric mean (range), 
parasite/μl
15,302
(1,241 – 200,000)
133,068
(1,000 – 194,000)
13,880
(1,000 – 196,000)
14,346
(1669 – 192000)
Haemoglobin, median (IQR), g/dL 10.1 (5.3 – 15.8) 10.2 (5.8 – 15.6) 10.0 (5.6 – 14.7) 10.1 (5.1 – 14.5)
Anemic at enrollment± 107 (39.3) 114 (34.5) 127 (38.5) 103 (35.4)
Abbreviations: CI, confidence interval; IQR, interquartile range.
*Data are presented as No. (%) unless otherwise indicated.
†Anaemia defined as haemoglobin of less than 10 g/dL.
Table 2: Treatment outcomes stratified by treatment group and day of follow-up
Outcome Measure by Day No./Total (%) of Patients [95% CI]
CQ SP AQ ASAQ
Day 14
Clinical failure ETF 14/309 (4.5) [2.6–7.3] 4/368 (1.1) [0.3–2.6] 2/372 (0.5) [0.1–1.7] 0/335 (0)
LCF 29/309 (9.4) [6.5–13.0] 2/368 (0.5) [0.1–1.7] 0/372 (0) 0/335 (0)
Parasitological failure LPF 56/309 (18.1) [14.1–22.7] 3/368 (0.8) [0.2–2.2] 0/372 (0) 0/335 (0)
Overall Treatment 
failure
99/309 (32.0) [27.0–37.4] 9/368 (2.4) [1.2–4.4] 2/372 (0.5) [0.1–1.7] 0/335 (0)
Day 28 Unadjusted by genotyping
Clinical failure ETF 14/300 (4.7) [2.7–7.5] 4/361 (1.1) [0.4–2.7] 2/356 (0.6) [0.1–1.8] 0/330 (0)
LCF 45/300 (15.0) [11.3–19.4] 4/361 (1.1) [0.4–2.7] 3/356 (0.8) [0.2–2.3] 4/330 (1.2) [0.4–2.9]
Parasitological failure LPF 104/300 (34.7) [29.4–40.2] 8/361 (2.2) [1.0–4.2] 6/356 (1.7) [0.7–3.5] 8/330 (2.4) [1.1–4.6]
Overall Treatment 
failure
163/300 (54.4) [48.7–59.9] 16/361 (4.4) [2.6–6.9] 11/356 (3.1) [1.6–5.3] 12/330 (3.6) [2.0–6.1]
Day 28 Adjusted by genotyping
Clinical failure ETF 14/300 (4.7) [2.7–7.5] 4/361 (1.1) [0.4–2.7] 2/356 (0.6) [0.1–1.8] 0/330 0 [0.4–2.7]
LCF 34/300 (11.3) [8.1–15.3] 3/361 (0.8) [0.2–2.2] 1/356 (0.3) [0–1.4] 2/330 (0.6) [0.1–2.0]
Parasitological failure LPF 84/300 (28.0) [23.1–33.3] 5/361 (1.4) [0.5–3.0] 3/356 (0.8) [0.2–2.3] 4/330 (1.2) [0.4–2.9]
Overall Treatment 
failure
132/300 (44.0) [38.5–49.7] 12/361 (3.3) [1.8–5.6] 6/356 (1.7) [0.7–3.5] 6/330 (1.8) [0.7–3.7]
CI: Confidence Interval; ETF: Early Treatment Failure; LCF: Late Clinical Failure; LPF: Late Parasitological Failure; CQ: Chloroquine; AQ: 
Amodiaquine; ASAQ: Artesunate + Amodiaquine; SP: Sulphadoxine-PyrimethamineMalaria Journal 2008, 7:55 http://www.malariajournal.com/content/7/1/55
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Secondary outcomes
Parasite clearance was more rapid with ASAQ than CQ,
AQ or SP until day 3 (P < 0.0001). Fever clearance was
delayed with CQ and SP, the proportion of febrile patients
being significantly lower with ASAQ and AQ until day-2.
The details are shown on Figure 4. On day-28, the extent
of haematological recovery (median of individual
increases in Hb) did not differ significantly between the
four groups (CQ, 0.8 g/dl, -4.1 to 4.9; SP, 1.0 g/dl, -4.8 to
6.4; AQ, 1.0 g/dl, -4.4 to 8.3; ASAQ, 0.9 g/dl, -6.0 to 6.4).
No severe side-effects attributable to the study medication
were observed during the follow-up period. Minor side
effects as vomiting were reported between day 1 and day
3 in seventeen patients (1.26%): 8 in the AQ group, 4 in
the CQ and the SP groups and 1 in the ASAQ group.
Discussion
As effective case management remains the cornerstone of
malaria elimination [18], the monitoring of antimalarial
drugs resistance is essential to ensure a continued cover-
age of effective antimalarial treatment. With the support
of resources from the Global Fund, the main objective of
the new RER was to set up an expanded programme to
monitor antimalarial drug resistance in Madagascar,
based on sentinel sites. The selected sentinel sites were
chosen at peripheral level (within public or private health
facilities) to be representative of the four epidemiological
strata in which the country could divided [19]. Because of
the size of the country and the availability of financial and
human resources, two sites were selected by epidemiolog-
ical stratum for establishing a surveillance system for in
vivo drug efficacy. Seven additional sites were secondly
incorporated in the RER for monitoring in vitro drug resist-
ance (in vitro drug sensitivity assay and molecular mark-
ers) to provide complementary data and warning signals
of the possible emergence of resistance or trends of declin-
ing drug efficacy.
The objective of the new RER was firstly to establish up-
dated baseline data on the efficacy of the antimalarial
drugs recommended by the MalMoH in its new Madagas-
car national policy. The methodology used was based on
the WHO 2003 protocol [15], with some modifications
(compromise between the high transmission and the low
to moderate transmission protocols): (i) children
enrolled in the study were aged between six months and
15 years and (ii) of P. falciparum parasitaemia on inclu-
sion was between 1,000 and 200,000/μl. The protocol
included randomized, 28-day follow-up with genotyping
to discriminate recrudescence from new infections, and
assessment of safety and tolerability. Despite the complex-
ity of conducting a multi-site study in Madagascar, an
Table 3: Treatment failures by Day 28 (adjusted by genotyping), stratified by age group
Treatment groups No. of treatment failure/Total of Patients (%) [95% CI]
Age groups Significance level P*
0.5 – 4 years ≥ 5 years
CQ 69/131 (52.6) [44.1–61.1] 63/169 (37.3) [30.2–44.7] 0.01
SP 8/171 (4.7) [2.2–8.7] 3/190 (1.6) [0.4–4.2] 0.57
AQ 4/174 (2.3) [0.7–5.5] 2/182 (1.1) [0.2–3.6] 0.64
ASAQ 4/161 (2.8) [0.8–5.9] 2/169 (1.2) [0.2–3.9] 0.51
CQ: Chloroquine; AQ: Amodiaquine; ASAQ: Artesunate + Amodiaquine; SP: Sulphadoxine-Pyrimethamine.
CI: Confidence Interval
Chi-square test for the comparison of two proportions
Table 4: CQ Treatment failures by Day 28 (adjusted by genotyping), stratified by age group and study site
CQ No. of treatment failure/Total of Patients (%) [95% CI]
0.5 – 4 years ≥ 5 years All age
Tropical Maevatanana 19/28 (67.9) [49.1–83.0] 9/24 (37.5) [20.1–57.8] 28/52 (53.8) [40.3–67.0]
Miandrivazo 10/16 (62.5) [37.6–83.2] 16/50 (32.0) [20.2–45.8] 26/66 (39.4) [28.2–51.5]
Highlands Moramanga 10/26 (38.5) [21.5–57.9] 3/10 (30.0) [8.3–62.0] 13/36 (36.1) [21.8–52.6]
Tsiroanomandidy 13/21 (61.9) [40.2–80.5] 9/17 (52.9) [29.7–75.2] 22/38 (57.9) [41.9–72.7]
Sub-desert Ejeda 14/20 (70.0) [47.7–86.8] 18/30 (60.0) [41.9–76.2] 32/50 (64.0) [50.1–76.4]
Ihosy 3/20 (15.0) [4.0–35.6] 8/38 (21.1) [10.3–36.1] 11/58 (19.0) [10.4–30.6]
CQ: Chloroquine. CI: Confidence Interval. Chi-square test for the comparison of two proportionsMalaria Journal 2008, 7:55 http://www.malariajournal.com/content/7/1/55
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excellent completion rates was achieved (> 93%) and
high-quality data were collected.
The four main antimalarial drugs used and recommended
by the NMCP were evaluated in five sites. In Tsiroano-
mandidy, ASAQ was not evaluated because this drug was
already assessed in another clinical trial [20] and in
Andapa and Farafangana, CQ was not evaluated for ethi-
cal reasons because of the too high frequency of treatment
failure found in the previous clinical trial in 2006.
Two methodological points could be underline by the
results of the study: (1) the necessity to extend the follow-
up to a minimum of 28 days (even more for drugs with a
prolonged duration of action) to avoid the underestima-
tion of the risk of treatment failure [21], i.e. for CQ, most
of the treatment failures occurred between 15 and 28 days
after treatment, a 14 day follow-up will underestimated
the OTF of 12% (32.0% for 14-days instead of 44.0% for
28-days) and (2) the necessity to enrol sufficient number
of patients to allow the stratification of the result based on
age (< 5 years and ≥ 5 years), i.e. the risk of CQ treatment
failure in children < 5 years was 2-fold more frequent than
in older patients (five to 15 years old), especially in mod-
erate to high transmission areas (Maevatanana and Mian-
drivazo).
This multi-site study represents the first extent in vivo drug
efficacy study performed in Madagascar since 1983 [22-
24]. The CQ efficacy was signifantly different between the
eight sites and ranged from moderate (Ihosy, 81%), inter-
mediate (Miandrivazo, 60.6% and Moramanga, 63.9%)
to low (Maevatanana, 46.2%; Tsiroanomandidy, 42.1%
and Ejeda, 36%), showing the important of the multi-site
studies. However, the results about the CQ efficacy were
comparable to those found previously in the last in vivo
trial carried out in Sainte Marie on the east coast in 2004
(36.9% of clinical failure within two weeks of CQ treat-
ment). Currently, CQ remains the drug most widely avail-
able (distribution and financial criteria) and is the first
drug used in most of areas in Madagascar at community
level, for treating acute fever before or without laboratory
diagnosis. According to Hastings et al [6], even with 50%
of efficacy, CQ might still be perceived as very effective at
community level, especially because of its antipyretic
activity that alleviate symptoms and because that most of
the recrudescence's which occur two to three week later
after the treatment are not perceived as a failure. Based on
these findings, the MalMoH must improve the HMM, as
Kaplan-Meier curve of cumulative treatment failure over the 28-day follow-up period, adjusted by genotyping Figure 3
Kaplan-Meier curve of cumulative treatment failure over the 28-day follow-up period, adjusted by genotyping.
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soon as possible, by withdrawing pre-packaged CQ and
gradually replacing it with pre-packaged ASAQ.
The results concerning the SP efficacy were more inform-
ative, contrasting with the good effectiveness reported in
previous studies in 2003–2004 [13,14]. The more worry-
ing was to finding even if the treatment failures were rare
that the ETFs were accounting for more than one third of
the SP treatment failure. There is no doubt that with the
increased drug use of SP in the next few years in Madagas-
car as IPT for pregnant women, the monitoring of its drug
resistance especially with the useful and reliable molecu-
lar makers such as Pf-dhfr and Pf-dhps [25] will be make it
a priority for the RER.
This study also confirmed that ASAQ, the first-line treat-
ment of the uncomplicated malaria recommended in
Madagascar was very effective, particularly because of the
excellent effectiveness of AQ, the partner drug associated
with artesunate. Although it was not feasible to monitor
for the potentially serious adverse effects associated with
amodiaquine such as neutropenia or hepatotoxicity (the
sample size was too small to exclude any clinically toxicity
with a low frequency such as < 1:100), ASAQ was well tol-
erated in the study population. This combination pro-
Proportions of patients with asexual parasites and fever (T° ≥ 37.5°C) on days of follow-up by treatment group Figure 4
Proportions of patients with asexual parasites and fever (T° ≥ 37.5°C) on days of follow-up by treatment group.
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duced also faster parasite and fever clearances than the
other antimalarial treatments. These findings constitute
important baseline data on the efficacy of this combina-
tion, a key tool within the framework of the elimination
of the malaria [18].
The results from this multi-site study show that antimalar-
ial drug resistance remains low in Madagascar, except for
CQ, compared to the bordering countries in the Indian
Ocean region such as the Comoros Archipelago [26,27].
The next step must be to complete these data by providing
the frequency of mutant parasites correlated with the CQ-
resistance (Pfcrt) or SP-resistance (Pf-dhfr or Pf-dhps) or
the in vitro response of parasites for drug for which no val-
idate molecular marker are available such as amodi-
aquine, artemisinin derivatives or amino alcohols
(quinine, lumefantrine). These complementary indicators
should allow the early detection of the spread of P. falci-
parum drug resistance, especially those introduced from
the Comoros Islands [28]. Indeed, the extension of the
RER at regional level is also crucial to enable the countries
of the region to share national information on antimalar-
ial drug efficacy and to help to minimize delays in imple-
menting national antimalarial drug policy change.
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